Colin Hill - 30 Jun 2026 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Reporting relationship: Director
Issuer ticker: FULC
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 16:30:07 UTC
Prior SEC filing: 30 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Alan Musso, as attorney-in-fact for Colin Hill

Key filing fact

Colin Hill filed Form 4 for Fulcrum Therapeutics, Inc. (FULC) on 02 Jul 2026.

Key facts

This page summarizes Colin Hill's Form 4 filing for Fulcrum Therapeutics, Inc. (FULC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 16:30.

Change

Previous filing in this sequence was filed on 30 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001673192 Primary reporting owner

Hill Colin

Relationship: Director
Address: C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE
Signature: /s/ Alan Musso, as attorney-in-fact for Colin Hill
Signature date: 02 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FULC transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +32,000
Change %
Price: $0.000000^*
Shares after: 32,000
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,000
Exercise price: $3.66
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.